

Discovery Sciences

Bio Book



At Syner-G, we've had the privilege of supporting clients across many stages of the drug development journey. Over the past few years, we've seen more and more early-stage teams looking for a partner who can help them move from scientific discovery to development with clarity and momentum. That's why we're introducing Discovery Sciences, a service line dedicated to supporting the earliest phases of drug innovation.

Discovery can be an exciting but uncertain time. Resources are often limited, timelines are tight, and decisions made in these early stages can shape the success of a program for years to come. Our Discovery Sciences experts are here to provide thoughtful, practical guidance, helping clients progress from hit identification to IND readiness with confidence.

We bring together expertise in lead optimization, compound design, ADME profiling, and vendor oversight, offering a cohesive, end-to-end approach. Our team works alongside biotech founders, R&D leaders, and scientific teams to reduce risk, streamline development, and keep programs moving forward.

We understand that every molecule, and every company, is different. Our goal is to be a steady partner through the complexities of early development, helping turn promising science into development-ready assets.

Sincerely,



Ron Kraus, CEO
Chief Executive Officer



Ron Kraus

Chief Executive Officer

What he says about the team at Syner-G:



"Every day, I am inspired by the innovative work our teams conduct as we guide sponsors on the complex journey of bringing new therapies to deserving patients."



Ron came to Syner-G in 2022 with 28 years of life science industry experience holding several executive leadership roles in both public and private equity-backed companies. Ron has broad global experience in the Bio/Pharma industry successfully serving in leadership roles as a Business Unit Head and Sales Executive. A common theme throughout his career is a passion for building expert teams and businesses providing unparalleled support in the development of life-saving therapies. What he says about the team at Syner-G: "Every day, I am inspired by the innovative work our teams conduct as we guide sponsors on the complex journey of bringing new therapies to deserving patients."

Prior to joining Syner-G, Ron was the Chief Operating Officer at Cytel, responsible for driving profitable growth of their Services business. At Parexel, he was the Global Head of Consulting, leading the 1000+ employee business on a robust growth journey via a combination of organic growth, entering new markets, and acquisitions.

Prior to Cytel, Ron held various positions spanning 25 years at Parexel where he consistently delivered high levels of growth through increased sales of existing services while developing new markets and expanding into new business areas. Under his leadership, the Consulting Services Business delivered 16% revenue CAGR at operating income levels exceeding 25%.

During his tenure leading Parexel Consulting, Ron successfully developed and launched Parexel's regulatory outsourcing service which exceeded expectations by capturing several new partnerships in the initial 18 months representing \$50M USD in new revenue. He also led the identification, due diligence, and integration of two acquisitions allowing Parexel to further differentiate its global product development services and provide access to new client buyers to drive growth.

During Ron's season in sales at Parexel he transformed the sales organization from a traditional business development function focused on RFP-style selling into an integrated global team highly effective at consultative selling and account management. While in Clinical Research Services Business, he oversaw Phase I thru Phase IV research and led the transformation of the function from a regionalbased service to a global function while enhancing operational and financial controls. These enhanced financial and operational controls delivered improved profitability and customer satisfaction and in 2019, Parexel's Clinical Research unit was ranked #1 among global CROs for leadership in Phase II-III services by ISR.

Ron graduated from the University of Massachusetts Amherst with a Bachelor of Science in Mechanical Engineering.

Under Ron's Leadership:

16% revenue CAGR

Consulting Services Business delivered 16% revenue CAGR at operating income levels exceeding 25%.

\$50M

Launched Parexel's regulatory outsourcing service capturing \$50M USD in new revenue

#1 (2019)

Parexel's Clinical Research unit ranked #1 among global CROs for leadership

Robert J. Maguire, PhD

**Director of Medicinal Chemistry
Drug Development Expert
Scientific Innovator**

His contributions have been instrumental in advancing novel drug candidates, optimizing synthetic routes, and reducing production costs.



Dr. Robert J. Maguire is an experienced medicinal chemist with nearly 30 years of experience in both large pharmaceutical companies and biotechnology organizations. Throughout his career, he has demonstrated scientific leadership across all stages of drug discovery, from early hit-to-lead programs through process development, cGMP manufacture, and CMC support for Phase 2 clinical candidates.

Dr. Maguire has worked across multiple therapeutic areas, including cancer, cardiovascular disease, immunology, and antibiotics, and has experience with a broad range of target classes. His work spans traditional small-molecule approaches—such as enzyme inhibitors, receptor modulators, and kinase targets—as well as more complex modalities including protein–drug conjugates. He has led in-house scientific teams and played a key role in the invention and advancement of multiple clinical candidates during his time at Pfizer and Cybrexa and currently supports several project teams as a Principal Consultant at Syner-G Biopharma Group.

In addition to his scientific leadership, Dr. Maguire has extensive experience managing complex networks of CROs, CDMOs, and external vendors to ensure the timely delivery of starting materials, intermediates, and drug substances. Among his notable achievements, he successfully scaled a clinical protein–drug conjugate candidate from 50 mg through toxicology and formulation studies to 250 g of cGMP material for IND submission and first-in-human trials within a 12-month timeframe.

Recognized for his commitment to innovation in synthetic chemistry, Dr. Maguire was selected at Pfizer to lead reaction optimization and technology application groups focused on improving the efficiency of drug production. His unique combination of medicinal chemistry expertise and CMC management experience enables seamless transitions from early discovery to Phase 2 development, while anticipating and mitigating downstream development and manufacturing challenges.

Beyond his professional work, Dr. Maguire is committed to mentorship and community engagement, actively supporting educational and vocational initiatives such as Junior Achievement of Southeast Connecticut.

30+ years

of experience spanning early-stage discovery to clinical supply

Expertise

Expertise extends across synthetic chemistry, route optimization, cGMP production, and external resource management

Michael Miller, Ph.D.

**Sr. Consultant,
Pharmaceutical Development**

Michael is a highly experienced discovery chemist, project leader, and manager with a strong track record of delivering successful scientific projects.



Michael Miller, Ph.D., joined Syner-G in 2019 as a highly experienced discovery chemist, project leader, and manager with a strong track record of delivering successful scientific projects from conception and preclinical evaluation through process development and scale-up.

He has significant experience in the design and synthesis of highly potent complex molecules and linkers for use in targeted drug delivery development of innovative therapeutics, leading to multiple molecules reaching clinical trials. He also has extensive experience managing research groups and creating collaborative, accountable interdisciplinary project teams, including CROs and partnered programs

Michael's areas of expertise include effectively leading drug substance (API) campaigns through selection and process transfer to CMOs by providing technical expertise and guidance, supporting phase appropriate CMC development to manufacture API and CTM. This includes working closely with multidisciplinary teams (drug product, analytical, and program management in collaboration with regulatory/QA functions) and the review and authoring of technical reports/source documents to support IND/IMPd filings. Additionally, Michael has significant experience in the synthetic design of novel therapeutic molecular classes (folates, taxoids, maytansinoids, benzodiazepines, etc.) and their structure activity relationships (SAR) to address potency, solubility, and tolerability pertaining to the development of antibody-drug conjugates.

He is a contributing author of 29 publications, 51 issued patents (including projects currently in clinical trials), and 39 scientific presentations. His special areas of interest are Medicinal/process Chemistry and Synthesis/development of molecules with biologic interest.

Areas of Expertise:

Leading drug
substance (API)
campaigns

Synthetic design of
novel therapeutic
molecular classes

(folates, taxoids, maytansinoids,
benzodiazepines, etc.)

Michael Has Completed:

29

Publications

39

Scientific
Presentations

51

Issued
Patents